Predictors of Asthma Control by Stepwise Treatment in Elderly Asthmatic Patients

Go-Young Ban,†* Young-Min Ye,†*
Yunhwan Lee,‡ Jeong-Eun Kim,‡
Young-Hee Nam,* Soo-Keol Lee,*
Joo-Hee Kim,*, Ki-Suck Jung,*,
Sang-Ha Kim,† Hae-Sim Park,† and the Premier Researchers Aiming New Era in Asthma and Allergic Diseases (PRANA) Study Group

1Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon; 2Department of Preventive Medicine & Public Health, Ajou University School of Medicine, Suwon; 3Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon; 4Department of Internal Medicine, Dong-A University School of Medicine, Busan; 5Department of Internal Medicine, Hallym University School of Medicine, Anyang; 6Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea

†Go-Young Ban and Young-Min Ye contributed equally to this work.

Received: 23 January 2015
Accepted: 15 April 2015

INTRODUCTION

The geriatric population is increasing worldwide. In the United States, the proportion of people over age 65 is projected to grow up to 25% of the population by 2050 (1) and in Korea, up to 40% until 2060 according to Statistics Korea (2). Although the prevalence of asthma in the elderly is similar to that in all adults (about 5% to 10%) (3), the severity and mortality of asthma are reported to increase with age (4, 5).

The greater mortality of asthma in elderly patients than in younger asthmatics is ascribed to several factors. Elderly asthmatic patients commonly have comorbidities, which make asthma treatment difficult in terms of drug-drug interactions, unintentional non-adherence resulting from complicated medication regimens, poor knowledge of the disease, and incorrect use of medications, especially inhalers (6-8). Another factor is intentional non-adherence that arises from excessive concern about medication complexity (6-8).

To reduce the severity and mortality of asthma in elderly asthmatic patients, we need to regulate the predictors of uncontrolled asthma. The predictors of uncontrolled asthma include old age, low socioeconomic status, smoking, obesity, low adherence, and comorbidities (rhinitis, sinusitis, reflux, and anxiety-depression) (9). However, little is known about predictors of asthma control in elderly patients, because most of the research excluded the elderly as subjects. In the present study, we designed a prospective, multicenter, real-life study to investigate whether comorbidities in elderly Korean asthmatic patients influence asthma control status, predictive factors for asthma control, and exacerbation during the Global Initiative for Asthma (GINA) guideline-based step-

Keywords: Elderly; Asthma; Control; Performance; Comorbidity

http://dx.doi.org/10.3346/jkms.2015.30.8.1042 • J Korean Med Sci 2015; 30: 1042-1047

ORIGINAL ARTICLE

Immunology, Allergic Disorders & Rheumatology

CrossMark

E-mail: hspark@ajou.ac.kr
Tel: +82.31-219-5150, Fax: +82.31-219-5154

Address for Correspondence:
Hae-Sim Park, MD
Department of Allergy & Clinical Immunology, Ajou University School of Medicine, 164 Worldcup-ro, Youngtong-gu, Suwon 443-380 Korea
Tel: +82.31-219-5150, Fax: +82.31-219-5154
E-mail: hspark@ajou.ac.kr

Funding: This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health and Welfare, ROK (HI14C1061), and IIT Grants from AstraZeneca Korea.
wise treatment (10) for 6 months in an elderly asthma cohort of Korea. In addition, we analyzed factors that affect the asthma-specific quality of life (A-QOL) which is a well-known tool for assessing the overall asthma treatment efficacy (11).

MATERIALS and METHODS

Study design and patients
The present study is a prospective, multicenter, non-interventional study from 5 centers in Korea from July 2011. A total of 296 patients aged 60 yr or older who were diagnosed with asthma at least 1 yr before enrollment were recruited for the study. After the subjects were enrolled, they received a stepwise treatment according to the GINA guideline (10) and were followed up every 3 months for 6 months.

The diagnosis of asthma was made on the basis of the GINA guideline (10). According to the GINA guideline (10), the improved-asthma control group (group A) was defined as a group of patients who had improved status (from uncontrolled to partly or well-controlled status or from partly controlled to well-controlled status) or maintained well-controlled status during the 6-month follow up, while the not-improved asthma control group (group B) was defined as the group of patients who did not improve.

Clinical data and comorbidities
We reviewed data on age, sex, body mass index (BMI), asthma duration, type and number of comorbidities, type and number of medications for asthma and comorbidities, smoking history, pulmonary function tests (PFTs), sputum analyses, and medication adherence for 1 yr before the enrollment. The medications for comorbid conditions and asthma that were administered for at least more than 90 days were counted, and only the asthma controllers or reliever medications defined by the GINA guideline (10) were considered asthma medications. Asthma medication before enrollment of each individual was classified as treatment step 1 to 5 according to the GINA guideline (10). After the enrollment, the asthma control test (ACT), A-QOL (12) questionnaire, the PFT, sputum analysis, and asthma control status based on the GINA guideline (10) were assessed 3 times at enrollment and every 3 months; in addition, the frequency of asthma exacerbation during the study period was monitored.

Current comorbidities and related medications were checked by reviewing patient medical records or self-reports. The comorbidities were classified by the system organ class (SOC) code. The medications for comorbidities were classified by the anatomical therapeutic chemical (ATC) classification according to the World Health Organization (13). There are 14 main groups for the first level of the ATC code: A alimentary tract, B blood and forming organs, C cardiovascular system, F anti-infectives, M musculoskeletal system, N nervous system, R respiratory system, and so on. Medication adherence was determined by the medication possession ratio (MPR) (14).

Asthma exacerbation was considered “present” if a patient had experienced hospitalization, emergency department visits, unscheduled visits, or more than 20 mg of oral corticosteroid intake for ≥ 3 days due to asthma symptom aggravation.

Geriatric assessment
To assess functional performance status or depression of elderly asthmatics, we performed geriatric assessment using the physical functioning (PF) scale and the Korean version of the short-form geriatric depression score (SGDS-K) at screening visits. The PF scale (15) is composed of 2 domains, mobility and self-care, which include 5 items in each domain (PF1: walking 400 meters, PF2: walking up 10 stairs without resting, PF3: stooping, crouching, or kneeling, PF4: reaching up over your head, PF5: lifting or carrying a bag of rice (8 kg), PF6: bathing or showering, PF7: dressing, PF8: getting in and out of bed or chairs, PF9: shopping for personal items or medications, PF10: riding bus or subway). Limitations in performing specific tasks on upper and lower body mobility, activities of daily living (ADL) and instrumental ADL (IADL) are also assessed. The summed PF score ranges from 0 to 100, with higher scores denoting higher levels of functioning (15). Depression was defined when the SGDS-K was > 9 (16).

Statistical analysis
Continuous variables were compared using Student’s t-test, and Pearson’s chi-square test or Fisher’s exact test was used for categorical variables. Binary logistic regression analysis was applied to assess predictors of changes in asthma control status and for asthma exacerbation. Univariate and multivariate general linear analyses were performed to assess factors for determining changes in A-QOL. Pearson correlation analysis was used to determine the factors related to A-QOL. All computations were performed using SPSS software version 20.0 (SPSS Inc., Chicago, IL, USA).

Ethics statement
This study was approved by Ajou University institutional review board (IRB No. MED-SUR-11-128), and the other 4 hospitals approved the study. Informed consent was obtained from each patient.

RESULTS

Clinical characteristics and comorbidities of the study patients
A total of 296 subjects were enrolled in the present study. Table 1 summarizes the clinical characteristics of the total study patients and comparisons between group A and B. The mean asth-
ma duration of the total study patients was 10 ± 4.4 yr. The number of current smokers was 19 (6.4%), and there were no significant differences in the proportion of smokers according to changes in asthma control status. The mean BMI was 23.9 ± 3.1 kg/m² in the total study population and it was not significantly different between group A and B. The mean sputum eosinophil and neutrophil counts at baseline were 12.7% ± 24.3% and 69.2% ± 31.5%, respectively. The mean sputum eosinophil count showed no significant difference between group A and B. The mean sputum eosinophil and neutrophil counts at baseline were 12.7% ± 24.3% and 69.2% ± 31.5%, respectively. The mean sputum eosinophil count showed no significant difference between the two groups, while the mean sputum neutrophil count was significantly lower in group A than in group B (14 (13.1%) vs. 11 (10.3%), respectively). The type and number of comorbidities and their SOC code did not show any differences in changes in asthma control status; however, the number of medications for comorbidities did. The numbers of patients administered ATC code R (n = 111, 49.8%), followed by C, A, B, M, N, and J (n = 39.7%, 73 [32.6%], 46 [20.5%], 36 [16.1%], 32 [14.3%], and 16 [7.1%], respectively). The type and number of comorbidities and their SOC code did not show any differences in changes in asthma control status; however, the number of medications for comorbidities did. The numbers of patients administered ATC code A, C, and M were significantly lower in group A than in group B (26 [36.1%] vs. 46 [63.9%], P = 0.002; 36 [40.9%] vs. 52 [59.1%], P = 0.009; and 12 [34.3%] vs. 23 [65.7%], P = 0.027). Treatment step before enrollment showed no significant difference between group A and B (Table 1).

**Table 1. Clinical characteristics of the study subjects**

| Characteristics                        | Total (n = 296) | Group A (n = 115) | Group B (n = 107) | P value |
|----------------------------------------|----------------|------------------|------------------|--------|
| Gender (Male/Female)                   | 149/147 (50.3/49.7) | 71/44 (61.7/38.3) | 54/53 (50.5/49.5) | 0.091  |
| Age (yr)                               | 69.9 ± 6.2 (60-93) | 69.7 ± 6.5       | 70.3 ± 6.3       | 0.499  |
| Medication adherence (%)               | 99.1 ± 6.5 (50-164.1) | 98.3 ± 5.3       | 99.7 ± 2.1       | 0.010  |
| Treatment step                          |                |                  |                  |        |
| Step 1                                 | 0              | 0                | 0                | -      |
| Step 2                                 | 40 (13.5%)     | 10 (8.7%)        | 14 (13.1%)       | 0.293  |
| Step 3                                 | 151 (51.0%)    | 57 (49.6%)       | 51 (47.7%)       | 0.777  |
| Step 4                                 | 104 (35.1%)    | 48 (41.7%)       | 41 (38.3%)       | 0.603  |
| Step 5                                 | 1 (0.3%)       | 0 (0%)           | 1 (0.9%)         | 0.299  |
| Number of co-morbidities               | 2.7 ± 2.0 (0-11) | 2.8 ± 2.0        | 3.0 ± 2.1        | 0.361  |
| Number of medication for comorbidities | 3.4 ± 3.8 (0-21) | 2.8 ± 3.3        | 4.5 ± 4.4        | 0.010  |
| PF scale                               | 85.7 ± 15.6 (13.3-100) | 89.8 ± 14.2      | 82.0 ± 16.4      | < 0.001 |
| Depression (GDS > 9)                   | 49 (16.6%)     | 17 (14.8%)       | 18 (16.8%)       | 0.715  |
| %FEV1 at baseline                      | 81.1 ± 26.3 (22.8-166.7) | 80.4 ± 27.9     | 76.7 ± 26.9     | 0.354  |
| ACT score at baseline                  | 19.7 ± 4.2 (6-25) | 20.2 ± 3.8       | 18.8 ± 4.8       | 0.015  |
| A-QOL at baseline                      | 93.1 ± 22.3 (20-120) | 96.4 ± 20.4      | 89.1 ± 23.9      | 0.016  |
| Asthma control status at baseline      |                |                  |                  |        |
| Uncontrolled                           | 37 (12.5)      | 18 (15.7%)       | 15 (14.0%)       | 1.000  |
| Partly controlled                      | 96 (32.4)      | 22 (19.1%)       | 46 (43.0%)       | 0.035  |
| Well controlled                        | 163 (55.1)     | 75 (65.2%)       | 46 (43.0%)       | 0.440  |
| The number of subjects who experienced asthma exacerbation for 6 months | 18 (6.1) | 4 (3.7%) | 13 (12.9%) | 0.021 |

Group A, the improved-asthma control group; Group B, the not-improved asthma control group; PF scale, physical functioning scale; GDS, geriatric depression score; ACT, asthma control test; A-QOL, asthma-specific quality of life. Values are presented as n (%) or mean ± standard deviation (range). P value is calculated by Pearson’s Chi-square test and the independent samples t-test.

**Fig. 1. Prevalence of comorbid conditions of study subjects. DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease.**

The predictors of changes in asthma control status

We analyzed predictors of asthma control status. By a univariate binary regression model using improved-asthma-control status as a dependent variable, we found the number of medications for comorbidities and total disease, PF scale score, and ACT score, and A-QOL at baseline were significant predictors (OR = 0.885, P = 0.002; OR = 0.904, P = 0.002; OR = 1.035, P < 0.001; OR = 1.081, P = 0.015; OR = 1.015, P = 0.017, respectively). Based on these findings, we tested a multivariate binary regression model. A small number of medications for comorbidities and a high PF scale score were predictors of changes in asthma control status (OR = 0.863, P = 0.004 and OR = 1.028,
The predictors of asthma exacerbation

The PF scale and ACT scores at baseline were the predictors of asthma exacerbation (OR = 0.969, P = 0.021 and OR = 0.900, P = 0.045, respectively). When we conducted a multivariate binary regression test with the PF scale score, ACT score, A-QOL, and FEV1 at baseline as variables, the ACT score at baseline was found to be a significant predictor of asthma exacerbation for the following 6 months (OR = 3.938, P = 0.048) (Table 3).

Factors affecting A-QOL

Table 4 presents factors that affect changes in A-QOL. Asthma duration (F = 5.656, P = 0.018), the ACT score (F = 12.237, P = 0.001) at baseline, and the presence of asthma exacerbation (F = 5.565, P = 0.019) during the study period were significant determinants of changes in A-QOL for the following 6 months. Each A-QOL at 0, 3, and 6 months was significantly correlated with the ACT score at 0, 3, and 6 months (r = 0.636, P < 0.001; r = 0.708, P < 0.001; and r = 0.725, P < 0.001, respectively). A positive correlation was found between changes in A-QOL and ACT scores during the study period (r = 0.549, P < 0.001). A-QOL at 0, 3, and 6 months showed negative correlations with the GDS (r = -0.453, P < 0.001) at screening and the number of medications for all diseases (r = -0.152, P = 0.023).

DISCUSSION

This is the first study to report predictors of changes in asthma control and exacerbation, and factors that affect A-QOL, with pharmacological treatment for 6 months in Korean elderly asthmatic patients. Our results indicate that less number of medications for comorbidities and higher PF scale can predict improved asthma control in elderly asthmatic patients. Moreover, the uncontrolled asthma status by the ACT score at baseline predicted asthma exacerbation for the following 6 months. Asthma duration, the ACT score at baseline, and the presence of asthma exacerbation were significant determinants of changes in A-QOL.

Regarding the clinical characteristics of the study population, there is no consistent definition for the elderly and researchers are using either 60 (17) or 65 yr old (18, 19) as criteria. The present study used 60 yr to define the elderly because we considered that this group of patients has the characteristics of the elderly population and enabled us to enroll a large number of patients. A previous study reported 75.7% of the study subjects adhere to asthma medication, which is lower than that of our result (19). Good adherence is a predictor of asthma control (17), while in the present study low medication adherence was noted in group A. This result attributed to use MPR for assessing medication adherence which lacks information about the proper use of inhalers. In addition, the present study investigated the changes in asthma control status which was different from the previous study (17), indicating that the patients who
were well controlled or improved in their asthma control status did not tend to adhere to asthma medications. Taken together, we can speculate that it is crucial to evaluate the administration technique of inhalers for elderly asthmatic patients in addition to the prescription rate, and to inform and educate patients about maintaining medications, even when their control status is well controlled or improved.

Comorbidities are essential factors for predicting asthma control (9, 20). The prevalence of comorbid conditions varies depending on study populations (17-19, 21). One study revealed rhinitis is the most prevalent comorbid condition (19), while the others reported hypertension was the most prevalent one, in concordance with the present study (17, 18). In addition, consistent with previous studies (17, 19), the present study found that the GDS score is negatively correlated with the ACT score and A-QOL. Similar to comorbidities, medications for comorbidities, including beta-blockers (22), and their numbers are crucial in asthma control (23, 24). A large number of medications are associated with unfavorable outcomes (6, 25, 26), therefore, it is recommended that treatment regimens should be as simple as possible for elderly asthmatic patients (27). A large number of medications for comorbidities may be ascribed to many comorbidities in the elderly and administration of more medications than clinically indicated (25). In the present study, there was no significant difference in the prevalence of comorbidities themselves, but significant difference in the number of administered medications between the 2 groups. Taken together, we can speculate that the number of medications can be a crucial predictor of asthma control in elderly patients rather than the sorts and number of comorbidities. Therefore, for better asthma control, it is essential to recognize the risks and poor outcomes of a greater number of medications and to clearly investigate all medications of each patient.

The low functional performance status of elderly asthmatics is associated with poor asthma outcome (19). In concordance with the prior study (19), the present study found that a high PF scale is a good predictor of improved asthma control. Among the items of the PF scale, the item instrumental activities of daily living is known to represent cognitive function of routine activities in the elderly, and these questionnaires are used to evaluate cognitive impairment in the field of neurology (28). Cognitive function of elderly patients affects disease control in terms of performance of action plans, correct use of medications and so on. Taken together, the functional performance status of elderly patients is a crucial factor for predicting asthma control status; therefore, we need to evaluate the functional performance status and to use the PF scale as appropriate tools for assessing asthma control status.

Current asthma control status and previous history of asthma exacerbation are known to predict the future risk of asthma exacerbation (9, 29). In addition, quality of life is reported to be positively associated with current asthma control status (25) and negatively with asthma exacerbation and asthma duration (26, 27). The present study found that current asthma control status predicted asthma exacerbation; however, the presence of asthma exacerbation at 3 months did not predict asthma exacerbation at 6 months (data was not shown), different from the results of previous studies (9, 29). A relatively short follow-up duration is suggested to contribute to this disparity of results. Moreover, in concordance with previous studies (25-27, 30), asthma control status, asthma duration, and asthma exacerbation were significant determinants of changes in A-QOL. Therefore, it is essential to control current asthma control status for less asthma exacerbation and better A-QOL.

A limitation of the present study is a relatively short study duration; therefore, further studies with a longer duration are warranted. The strong point of the present study is the study subjects’ characteristics. The subjects enrolled in our study are a real world asthma population, unlike most of the clinical trials or well-organized studies involving nonsmokers and younger patients that represent only a small percentage of the real asthma population. Thus, our study showed more reliable results that can be used in clinical practice. In addition, the present study focused on changes in asthma control status as a main outcome, and the prospective study design make it possible that the findings may be more useful in practice.

In conclusion, the number of medications for comorbidities and functional status determined by the PF scale are considered important parameters for assessing and predicting asthma control status in elderly asthmatic patients. In addition, multifactorial assessment of medications is essential in the treatment of elderly asthmatic patients.

DISCLOSURE

All of the authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Research conception and study design: Ye YM, Park HS. Enrollment of subjects: Ban GY, Ye YM, Lee Y, Kim JE, Nam YH, Lee SK, Kim JH, Jung KS, Kim SH, Park HS. Data analysis and drafting: Ban GY, Ye YM, Park HS. Approval of manuscript: all authors

ORCID

Ga-Young Ban http://orcid.org/0000-0002-7961-742X
Young-Min Ye http://orcid.org/0000-0002-7517-1715
Hae-Sim Park http://orcid.org/0000-0003-2614-0303
REFERENCES

1. Hanania NA, King MJ, Braman SS, Saltoun C, Wise RA, Enright P, Falsey AR, Mathur SK, Ramsdell JW, Rogers L, et al.; Asthma in Elderly workshop participants. Asthma in the elderly: Current understanding and future research needs—a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol 2011; 128: S4-24.

2. Statistics Korea. Population projections. 2014. Available at https://www.index.go.kr/egams/stts/jsp/stts/PO_STTS_IdxMain.jsp?idx_cd=1010&bbs=INDX_01 [accessed on May 14 2014].

3. Reed CE. Asthma in the elderly: diagnosis and management. J Allergy Clin Immunol 2010; 126: 681-7; quiz 8-9.

4. Tsai CL, Delclos GL, Huang JS, Hanania NA, Camargo CA Jr. Age-related differences in asthma outcomes in the United States, 1988-2006. Ann Allergy Asthma Immunol 2013; 110: 240-6, e1.

5. Yáñez A, Cho SH, Soriano JB, Rosenwasser LJ, Rodrigo GJ, Rabe KF, Peeters S, Niimi A, Ledford DK, Katalir R, et al. Asthma in the elderly: what we know and what we have yet to know. World Allergy Organ J 2014; 7: 8.

6. Jones SC, Iverson D, Burns P, Evers U, Caputi P, Morgan S. Asthma and ageing: an end user’s perspective—the perception and problems with the management of asthma in the elderly. Clin Exp Allergy 2011; 41: 471-81.

7. Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med 2013; 107: 1481-90.

8. Goeman DP, Douglass JA. Optimal management of asthma in elderly patients: strategies to improve adherence to recommended interventions. Drugs Aging 2007; 24: 381-94.

9. Schatz M. Predictors of asthma control: what can we modify? Curr Opin Allergy Clin Immunol 2012; 12: 263-8.

10. Global Initiative for Asthma. Global strategy for asthma management and prevention 2014 (revision). 2014. Available at http://www.ginasthma.org/documents/4 [accessed on May 14 2014].

11. Braido F, Bousquet PJ, Brozova Z, Canonica GW, Compalati E, Fiocchi A, Fokkens W, Gerth van Wijk R, La Grutta S, Lombardi C, et al. Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA(2)LEN taskforce position paper. Allergy 2010; 65: 959-68.

12. Lee EH, Kim SH, Choi JH, Lee YK, Nahm DH, Park HS. Development and evaluation of an Asthma-Specific Quality of Life (A-QOL) questionnaire. J Asthma 2009; 46: 716-21.

13. WHO Collaborating Center for Drug Statistics Methodology. Updates included in the ATC/DDD Index. Available at http://www.whocc.no/atc_ddd_index/?code=&showdescription=yes [accessed on May 14 2014].

14. Hwang EK, Jin HJ, Nam YH, Shin YS, Yoon SK, Lee YK, Nahm DH, Park HS. The predictors of poorly controlled asthma in elderly. Allergy Asthma Immunol Res 2012; 4: 270-6.

15. Lee YH, Lee KJ, Han GS, Yoon SJ, Lee YK, Kim CH, Kim JL. The development of physical functioning scale for community-dwelling older persons. Korean J Prev Med 2002; 35: 359-74.

16. Lee H, Kahng S, Lee J. The effects of socioeconomic position and health behavior on geriatric depressive symptom. J Korean Gerontol Soc 2008; 28: 1129-45.

17. Krauskopf KA, Sofianou A, Goel MS, Wolf MS, Wilson EA, Martyrenko ME, Halm EA, Leventhal H, Feldman JM, Federman AD, et al. Depressive symptoms, low adherence, and poor asthma outcomes in the elderly. J Asthma 2013; 50: 260-6.

18. Park J, Kim TB, Joo H, Lee JS, Lee SD, Oh YM. Diseases concomitant with asthma in middle-aged and elderly subjects in Korea: a population-based study. Allergy Asthma Immunol Res 2013; 5: 16-25.

19. Ross JA, Yang Y, Song PX, Clark NM, Baptist AP. Quality of life, health care utilization, and control in older adults with asthma. J Allergy Clin Immunol Pract 2013; 1: 157-62.

20. Lee YK. Comorbid diseases in adult asthma. Allergy Asthma Immunol Res 2013; 5: 1-2.

21. Kim YH, Lee MK, Lee SJ, Cho MS, Hwang MS. Medication status and adherence of the elderly under home care nursing. J Korean Acad Community Health Nurs 2011; 22: 290-301.

22. Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute beta-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest 2014; 145: 779-86.

23. Hajjar ER, Caferro AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5: 345-51.

24. Enright PL. The diagnosis and management of asthma is much tougher in older patients. Curr Opin Allergy Clin Immunol 2002; 2: 175-81.

25. Guilbert TW, Garris C, Jhingran P, Bonafede M, Tomaszewski KJ, Bonus T, Hahn RM, Schatz M. Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life. J Asthma 2011; 48: 126-32.

26. Wilson SR, Rand CS, Cabana MD, Fogg MB, Halterman JS, Olson L, Vollmer WM, Wright RI, Taggart V. Asthma outcomes: quality of life. J Allergy Clin Immunol 2012; 129: S88-123.

27. Choi JI, Hwang SY. Factors associated with health-related quality of life among low-compliant asthmatic adults in Korea. Res Nurs Health 2009; 32: 140-7.

28. Gold DA. An examination of instrumental activities of daily living assessment in older adults and mild cognitive impairment. J Clin Exp Neuropsychol 2012; 34: 11-34.

29. Guilbert TW, Garris C, Jhingran P, Bonafede M, Tomaszewski KJ, Bonus T, Hahn RM, Schatz M. Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life. J Asthma 2011; 48: 126-32.

30. Lowery EP, Henneberger PK, Rosiello R, Sama SR, Preusse P, Milton GK. Quality of life of adults with workplace exacerbation of asthma. Qual Life Res 2007; 16: 1605-13.